Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

NCT02992743 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: letetresgene autoleucel (GSK3377794)
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

GlaxoSmithKline